SCHEMBL5651716

SCHEMBL5651716

CCN(CC)CCCNC(=O)c1ccc(-c2nc3c(Cl)cc(C(F)(F)F)cc3[nH]2)c(OC)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
METAP2 P50579 2/20 0.49
HTT P42858 2/20 0.47
PRMT5 O14744 1/20 0.45
WDR77 Q9BQA1 1/20 0.45
ROCK2 O75116 4/20 0.43
ROCK1 Q13464 4/20 0.43
CYP1A2 P05177 1/20 0.41
TMEM97 Q5BJF2 1/20 0.41
SIGMAR1 Q99720 1/20 0.41
TDP1 Q9NUW8 1/20 0.40
TACR2 P21452 1/20 0.40
TACR1 P25103 1/20 0.40
HDAC4 P56524 1/20 0.40
HDAC2 Q92769 1/20 0.40
HDAC8 Q9BY41 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
TP53 P04637 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
CYP3A4 P08684 1/20 0.39
CYP2C9 P11712 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5647607 0.93 HTT (0.43) METAP2HTTPRMT5WDR77TACR2
SCHEMBL5650786 0.90 METAP2 (0.47) METAP2HTTTACR2TACR1HDAC4
SCHEMBL5653019 0.90 METAP2 (0.46) METAP2HTTPRMT5WDR77TACR2
SCHEMBL5649037 0.89 METAP2 (0.50) METAP2ROCK2ROCK1CYP1A2MRGPRX4
SCHEMBL5651724 0.88 HTT (0.47) METAP2HTTPRMT5WDR77ROCK2
SCHEMBL5653988 0.86 FLT3 (0.51) METAP2HTTPRMT5WDR77ROCK2
SCHEMBL5647974 0.86 HDAC6 (0.50) HTTTMEM97SIGMAR1TACR2TACR1
SCHEMBL5654000 0.85 HTT (0.49) METAP2HTTPRMT5WDR77ROCK2
SCHEMBL5650247 0.83 PRSS12 (0.50) HTTPRMT5WDR77ROCK2ROCK1
SCHEMBL5650711 0.83 FLT3 (0.47) METAP2MRGPRX4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7220769-B2 Azolylbenzamides and analogues and their use for treating osteoporosis NIKEM RESEARCH S.R.L. (IT) 2007-05-22 US disclosed
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis 3-V BIOSCIENCES, INC. 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis NR0B2, NR0B1, NCOR1 METAP2 3311/4885HTT 4354/4885PRMT5 448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.